Additionally, bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, was FDA-approved for the treatment of recurrent glioblastoma in 2009 (Kreisl et al., 2009). This evidence concerns the gene VEGFA and glioblastoma.